Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2015

View Archived Issues

ATRX gene mutations identified as a potential biomarker for clinically aggressive PCC/PGL

Ono Pharmaceutical updates progress of third quarter of fiscal 2014

Shionogi reports milestones of third quarter of fiscal 2014

Isis Pharmaceuticals reports data from phase II study of ISIS-PTP1B Rx in type 2 diabetes

Belsomra now available in the U.S. to treat insomnia

InMed begins program targeting Epidermolysis bullosa simplex

ACEA Biosciences patents BTK inhibitors

CytoDyn concludes phase II PRO-140 trial and submits phase III protocol to FDA

Leading BioSciences cleared to begin phase II study of LB-1148 in septic shock

Regulus earns milestone payment under Biogen Idec research collaboration

Launch of new biotech start-up OptiKira

Diamyd Medical starts pilot trial of type 1 diabetes vaccine injected into lymph nodes

BioLight updates development progress of tests for bladder cancer and dry eye

Wound care specialist AlliquaBioMedical agrees to acquire device developer Celleration

NIHR and Janssen to study rheumatoid arthritis response to anti-TNF therapy

Polaris initiates phase I trial of ADI-PEG20 plus FOLFOX in gastrointestinal cancers

U.S. researchers prepare new deuterated droxidopa derivatives

Amgen releases topline results from phase III study of adalimumab biosimilar ABP-501

Scientists at BMS disclose XIAP inhibitors

New AXL kinase inhibitors patented by Ono Pharmaceuticals

Cynata's mesenchymal stem cells to be tested in animal model of lung fibrosis

Obinutuzumab extends PFS in phase III indolent non-Hodgkin's lymphoma trial

FDA accepts for review CSL Behring's BLA for rIX-FP

New data presented for an inhibitor of tau aggregation in Alzheimer's disease treatment

rEVO Biologics funds pre-eclampsia research center at Yale University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...